Linking human Dead end 1 (DND1) variants to male infertility employing zebrafish embryos.

Dead end azoospermia male infertility non-obstructive azoospermia teratoma whole-exome sequencing zebrafish

Journal

Human reproduction (Oxford, England)
ISSN: 1460-2350
Titre abrégé: Hum Reprod
Pays: England
ID NLM: 8701199

Informations de publication

Date de publication:
03 04 2023
Historique:
received: 30 06 2022
revised: 16 01 2023
medline: 4 4 2023
pubmed: 23 2 2023
entrez: 22 2 2023
Statut: ppublish

Résumé

Is the vertebrate protein Dead end (DND1) a causative factor for human infertility and can novel in vivo assays in zebrafish help in evaluating this? Combining patient genetic data with functional in vivo assays in zebrafish reveals a possible role for DND1 in human male fertility. About 7% of the male population is affected by infertility but linking specific gene variants to the disease is challenging. The function of the DND1 protein was shown to be critical for germ cell development in several model organisms but a reliable and cost-effective method for evaluating the activity of the protein in the context of human male infertility is still missing. Exome data from 1305 men included in the Male Reproductive Genomics cohort were examined in this study. A total of 1114 of the patients showed severely impaired spermatogenesis but were otherwise healthy. Eighty-five men with intact spermatogenesis were included in the study as controls. We screened the human exome data for rare, stop-gain, frameshift, splice site, as well as missense variants in DND1. The results were validated by Sanger sequencing. Immunohistochemical techniques and, when possible, segregation analyses were performed for patients with identified DND1 variants. The amino acid exchange in the human variant was mimicked at the corresponding site of the zebrafish protein. Using different aspects of germline development in live zebrafish embryos as biological assays, we examined the activity level of these DND1 protein variants. In human exome sequencing data, we identified four heterozygous variants in DND1 (three missense and one frameshift variant) in five unrelated patients. The function of all of the variants was examined in the zebrafish and one of those was studied in more depth in this model. We demonstrate the use of zebrafish assays as a rapid and effective biological readout for evaluating the possible impact of multiple gene variants on male fertility. This in vivo approach allowed us to assess the direct impact of the variants on germ cell function in the context of the native germline. Focusing on the DND1 gene, we find that zebrafish germ cells, expressing orthologs of DND1 variants identified in infertile men, failed to arrive correctly at the position where the gonad develops and exhibited defects in cell fate maintenance. Importantly, our analysis facilitated the evaluation of single nucleotide variants, whose impact on protein function is difficult to predict, and allowed us to distinguish variants that do not affect the protein's activity from those that strongly reduce it and could thus potentially be the primary cause for the pathological condition. These aberrations in germline development resemble the testicular phenotype of azoospermic patients. The pipeline we present requires access to zebrafish embryos and to basic imaging equipment. The notion that the activity of the protein in the zebrafish-based assays is relevant for the human homolog is well supported by previous knowledge. Nevertheless, the human protein may differ in some respects from its homologue in zebrafish. Thus, the assay should be considered only one of the parameters used in defining DND1 variants as causative or non-causative for infertility. Using DND1 as an example, we have shown that the approach described in this study, relying on bridging between clinical findings and fundamental cell biology, can help to establish links between novel human disease candidate genes and fertility. In particular, the power of the approach we developed is manifested by the fact that it allows the identification of DND1 variants that arose de novo. The strategy presented here can be applied to different genes in other disease contexts. This study was funded by the German Research Foundation, Clinical Research Unit, CRU326 'Male Germ Cells'. There are no competing interests. N/A.

Identifiants

pubmed: 36807972
pii: 7048706
doi: 10.1093/humrep/dead031
doi:

Substances chimiques

Dnd1 protein, human 0
Neoplasm Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

655-670

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Kim Joana Westerich (KJ)

Institute of Cell Biology, Center for Molecular Biology of Inflammation, University of Münster, Münster, Germany.

Solveig Reinecke (S)

Institute of Cell Biology, Center for Molecular Biology of Inflammation, University of Münster, Münster, Germany.

Jana Emich (J)

Institute of Reproductive Genetics, University of Münster, Münster, Germany.

Margot Julia Wyrwoll (MJ)

Institute of Reproductive Genetics, University of Münster, Münster, Germany.

Birgit Stallmeyer (B)

Institute of Reproductive Genetics, University of Münster, Münster, Germany.

Matthias Meyer (M)

Evolutionary Genetics Department, Max-Planck-Institute for Evolutionary Anthropology, Leipzig, Germany.

Manon S Oud (MS)

Department of Human Genetics, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, The Netherlands.

Daniela Fietz (D)

Institute of Veterinary Anatomy, Histology and Embryology, Justus Liebig University, Gießen, Germany.

Adrian Pilatz (A)

Clinic for Urology, Pediatric Urology and Andrology, Justus Liebig University, Gießen, Germany.

Sabine Kliesch (S)

Department of Clinical and Surgical Andrology, Centre of Reproductive Medicine and Andrology, University of Münster, Münster, Germany.

Michal Reichman-Fried (M)

Institute of Cell Biology, Center for Molecular Biology of Inflammation, University of Münster, Münster, Germany.

Katsiaryna Tarbashevich (K)

Institute of Cell Biology, Center for Molecular Biology of Inflammation, University of Münster, Münster, Germany.

Tamara Limon (T)

Institute of Cell Biology, Center for Molecular Biology of Inflammation, University of Münster, Münster, Germany.

Martin Stehling (M)

Flow Cytometry Unit, Max-Planck-Institute of Molecular Biomedicine, Münster, Germany.

Corinna Friedrich (C)

Institute of Reproductive Genetics, University of Münster, Münster, Germany.

Frank Tüttelmann (F)

Institute of Reproductive Genetics, University of Münster, Münster, Germany.

Erez Raz (E)

Institute of Cell Biology, Center for Molecular Biology of Inflammation, University of Münster, Münster, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH